The disclosed and claimed subject matter relates to organometallic amidinate and guanidinate paddlewheel compounds, compositions containing the compounds and methods of using the compounds as precursors for deposition of metal-containing films.

The present invention relates to a new amorphous material with advantageous properties as charge transport material and/or absorber material for various applications, in particular in photoelectric conversion devices, i.e. an amorphous material of the composition (R.sup.1NR.sup.2.sub.3).sub.5Me X.sup.1.sub.aX.sup.2.sub.b wherein R.sup.1 is C.sub.1-C.sub.4-alkyl, R.sup.2 are independently of one another hydrogen or C.sub.1-C.sub.4-alkyl, Me is a divalent metal, X.sup.1 and X.sup.2 have different meanings and are independently of one another selected from F, CI, Br, I or a pseudohalide, a and b are independently of one another 0 to 7, wherein the sum of a and b is 7.

The present invention relates to a new amorphous material with advantageous properties as charge transport material and/or absorber material for various applications, in particular in photoelectric conversion devices, i.e. an amorphous material of the composition (R.sup.1NR.sup.2.sub.3).sub.5Me X.sup.1.sub.aX.sup.2.sub.b wherein R.sup.1 is C.sub.1-C.sub.4-alkyl, R.sup.2 are independently of one another hydrogen or C.sub.1-C.sub.4-alkyl, Me is a divalent metal, X.sup.1 and X.sup.2 have different meanings and are independently of one another selected from F, CI, Br, I or a pseudohalide, a and b are independently of one another 0 to 7, wherein the sum of a and b is 7.

The invention provides a composition containing hyaluronic acid (HA) or a pharmaceutically-acceptable salt thereof preserved with a cationic preservative and related methods. In one embodiment, the pharmaceutically-acceptable salt is sodium hyaluronate. In another embodiment, the cationic preservative includes benzalkonium chloride (BAK).

In some embodiments, the present disclosure pertains to a compound, comprising a transition metal complex having the formula -[M (x,y)-L.sub.1 (w,v)-L.sub.2 (t,u)-L.sub.3].sup.p+An.sup..sub.mZ.sup..sub.pm. In an embodiment of the present disclosure may be . In another embodiment may be . In some embodiments of the present disclosure, M is a transition metal. In a related embodiment, p is an integer corresponding to the oxidation state of M. In some embodiments of the present disclosure, each of x, y, w, v, t, and u independently comprise R. In other embodiments, each of x, y, w, v, t, and u independently comprise S. In an embodiment of the present disclosure, each of L.sub.1, L.sub.2, and L.sub.3 independently is a ligand comprising a substituted diamine. In some embodiments, An.sup. comprises a lipophilic anion, where m is from 1 to 3, and where Z.sup. comprises an optional second anion.

In some embodiments, the present disclosure pertains to a compound, comprising a transition metal complex having the formula -[M (x,y)-L.sub.1 (w,v)-L.sub.2 (t,u)-L.sub.3].sup.p+An.sup..sub.mZ.sup..sub.pm. In an embodiment of the present disclosure may be . In another embodiment may be . In some embodiments of the present disclosure, M is a transition metal. In a related embodiment, p is an integer corresponding to the oxidation state of M. In some embodiments of the present disclosure, each of x, y, w, v, t, and u independently comprise R. In other embodiments, each of x, y, w, v, t, and u independently comprise S. In an embodiment of the present disclosure, each of L.sub.1, L.sub.2, and L.sub.3 independently is a ligand comprising a substituted diamine. In some embodiments, An.sup. comprises a lipophilic anion, where m is from 1 to 3, and where Z.sup. comprises an optional second anion.

In an embodiment, the present disclosure pertains to a composition having a cation and an anion. In some embodiments, a base is incorporated into the anion, and the cation and the anion form a bifunctional catalyst. In some embodiments, the cation is a chiral cobalt(III) species, and a nitrogenous Brpnsted base is incorporated into counter anions of the chiral cobalt(III) species cation. In some embodiments, the bifunctional catalyst is a tricationic cobalt(III) hydrogen bond donor catalyst, and a nitrogenous Brpnsted base is incorporated into counter anions of the tricationic cobalt(III) hydrogen bond donor catalyst. In another aspect, the present disclosure pertains to a bifunctional catalyst having a smart anion with a cationic metal species. In some embodiments, the smart anion performs a specific role in a chemical reaction without the inclusion of additional external components to accomplish a same specific role in the chemical reaction.

The present disclosure provides compositions, methods, and devices for sensing, detecting, and/or selectively capturing phosphate from water. An exemplary method includes: contacting a ligand or a rare earth metal complex of a ligand as described herein with an aqueous phosphate-containing medium at a pH of 5 to 12 under conditions sufficient to bind phosphate (e.g., reversibly bind phosphate). In certain embodiments, the method further includes releasing the bound phosphate by contacting the bound phosphate complex with an aqueous medium at a pH of 0 to 4 under conditions sufficient to release the bound phosphate.

The present disclosure provides compositions, methods, and devices for sensing, detecting, and/or selectively capturing phosphate from water. An exemplary method includes: contacting a ligand or a rare earth metal complex of a ligand as described herein with an aqueous phosphate-containing medium at a pH of 5 to 12 under conditions sufficient to bind phosphate (e.g., reversibly bind phosphate). In certain embodiments, the method further includes releasing the bound phosphate by contacting the bound phosphate complex with an aqueous medium at a pH of 0 to 4 under conditions sufficient to release the bound phosphate.

According to the present invention, there is a demand for novel platinum(IV) complex which has sufficient water-solubility, stability, antitumor activity, and the like that are required as a medicine, and may be used clinically. Thus, provided is a platinum(IV) complex represented by the following General Formula (I) [wherein X.sub.1 and X.sub.2 each represent a halogen atom or are bonded together to form a dicarboxylate selected from the group consisting of oxalate, malonate, succinate, and o-phthalate; and Y represents a halogen atom.

##STR00001##